British drugmaker GSK said it has no plans to reintroduce its once top-selling heartburn medication Zinetac (ranitidine) brand in India, despite the US court last week ruling that there is no sound scientific evidence to back the claims that the drug increases the risk of cancer.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uMB6S7c
via IFTTT
0 comments:
Post a Comment